mas825
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jun 7, 2019 (NCT04665154)
Timeline
Indications
Mechanism of action
- Interleukin-18INHIBITOR
IL18 inhibitor
- Interleukin-1 alphaINHIBITOR
IL1A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07203001 | Phase 2 | Nov 3, 2025 | Novartis |
| NCT06097663 | Phase 2 | Feb 9, 2024 | Novartis |
| NCT06309823 | Phase 3 | Feb 8, 2023 | University of Toronto |
| NCT04641442 | Phase 2 | Dec 17, 2020 | Novartis |
| NCT04382651 | Phase 2 | May 15, 2020 | Novartis |
| NCT04665154 | Phase 1 | Jun 7, 2019 | Novartis |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 5 | 5 | 2 | 2019 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1